Recall of NM Implantable Pulse Generator within the Infinity and Proclaim device families

According to Department of Health, Therapeutic Goods Administration, this recall involved a device in Australia that was produced by St Jude Medical Australia Pty Ltd.

What is this?

A correction or removal action taken by a manufacturer to address a problem with a medical device. Recalls occur when a medical device is defective, when it could be a risk to health, or when it is both defective and a risk to health.

Learn more about the data here
  • Type of Event
  • Event ID
  • Event Risk Class
    Class II
  • Event Initiated Date
  • Event Country
  • Event Source
  • Event Source URL
  • Notes / Alerts
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Extra notes in the data
  • Reason
    Abbott has become aware of instances in which the elective replacement indicator (eri) in some devices has triggered earlier than intended. in these cases, the eri alerts were triggered early due to an error in how the device calculates the actual remaining battery life in the impacted implantable pulse generators (ipg). eri alerts estimate battery life based on programmed device parameters and patient usage and are unique to each patient. importantly, please note that this issue is an error in software calculation and is not an indication of the devices’ actual battery performance. currently, all implanted ipgs within the infinity and proclaim families are affected by this issue.
  • Action
    1. If an ERI message is displayed on the PC, contact Abbott to obtain the device-specific generator logs and to conduct the ERI Assessment using the steps supplied in the letter. 2. Follow-up communication from Abbott will be provided in order to make appropriate decisions. Either by: - ERI is valid at this time for this device, follow existing information provided by IFU and CP for the elective replacement window for this device. - The device has the appropriate level of battery voltage to provide the existing therapy until the next assessment, which should occur no later than March 2018. During this period, the ERI message will be displayed on the PC at the start of each session and may be dismissed. 3. Abbott will deploy a software upgrade that addresses the errors in calculation causing the inappropriate ERI message. Notification of the availability of this software update will occur through the Apple Public App Store for the PC and through the SJM App Catalogue for the CP.


  • Model / Serial
    NM Implantable Pulse Generator within the Infinity and Proclaim device familiesRecall for product correctionARTG Numbers: 277755, 277756 Hazard AlertImplantable Pulse Generator ARTG Numbers: 279015, 279016, 282999, 283000, 289235, 278846, 278847, 278849 and 278850
  • Manufacturer


  • Manufacturer Parent Company (2017)
  • Manufacturer comment
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source